DYN
DYN
NASDAQ · Biotechnology

Dyne Therapeutics Inc

$17.88
+0.32 (+1.82%)
As of Mar 24, 1:30 PM ET ·
Financial Highlights (FY 2025)
Revenue
618.44M
Net Income
86.92M
Gross Margin
54.7%
Profit Margin
14.1%
Rev Growth
+16.5%
D/E Ratio
0.27
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 54.7% 54.7% 54.7%
Operating Margin 17.6% 18.5% 16.5%
Profit Margin 14.1% 16.3% 14.7%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 618.44M 584.19M 668.57M
Gross Profit 338.11M 319.39M 365.52M
Operating Income 108.84M 108.19M 110.48M
Net Income 86.92M 95.40M 98.23M
Gross Margin 54.7% 54.7% 54.7%
Operating Margin 17.6% 18.5% 16.5%
Profit Margin 14.1% 16.3% 14.7%
Rev Growth +16.5% -3.4% +9.6%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 283.02M 259.89M 325.33M
Total Equity 1.06B 1.15B 977.37M
D/E Ratio 0.27 0.23 0.33
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 124.54M 120.89M 157.55M
Free Cash Flow 66.24M 92.85M 89.99M